Core Insights - Alumis Inc. is a late-stage biopharma company focused on developing next-generation targeted therapies for immune-mediated diseases [2] - The company is leveraging a proprietary data analytics platform to create a pipeline of oral tyrosine kinase 2 inhibitors and other therapies [2] Company Overview - Alumis is developing envudeucitinib (formerly ESK-001) for systemic immune-mediated disorders, including moderate-to-severe plaque psoriasis and systemic lupus erythematosus [2] - The pipeline also includes A-005 for neuroinflammatory and neurodegenerative diseases, and lonigutamab for thyroid eye disease [2] - Several preclinical programs are being identified through a precision approach [2] Upcoming Events - Alumis will participate in the Guggenheim's 2nd Annual Healthcare Innovation Conference from November 10-12, 2025, with a fireside chat scheduled for November 11, 2025, at 1:30 pm ET [4] - The company will also present at the Stifel 2025 Healthcare Conference from November 11-13, 2025, on November 12, 2025, at 2:00 pm ET [4]
Alumis to Participate in Upcoming November Investor Conferences